InspireMD, Inc. $NSPR Shares Bought by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC increased its stake in InspireMD, Inc. by 37.1%, now owning approximately 3.82% of the company, valued at $3.15 million.
• InspireMD's stock has recently been rated as "Buy" by analysts, despite Piper Sandler lowering its price target from $4.50 to $4.00.
• Company insiders have purchased a total of 103,304 shares worth approximately $250,000 over the last three months, increasing their overall ownership to 34.06% of the firm's stock.

Parkman Healthcare Partners LLC boosted its holdings in shares of InspireMD, Inc. (NYSE:NSPR - Free Report) by 37.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,171,416 shares of the company's stock after acquiring an additional 316,700 shares during the period. Parkman Healthcare Partners LLC owned 3.82% of InspireMD worth $3,151,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NSPR. Nantahala Capital Management LLC grew its stake in InspireMD by 38.4% during the 1st quarter. Nantahala Capital Management LLC now owns 2,318,017 shares of the company's stock valued at $6,235,000 after acquiring an additional 643,452 shares in the last quarter. Huntleigh Advisors Inc. acquired a new position in InspireMD in the 1st quarter valued at about $316,000. Courier Capital LLC acquired a new position in InspireMD in the 1st quarter valued at about $81,000. Northern Trust Corp boosted its holdings in InspireMD by 103.7% in the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after purchasing an additional 24,452 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its holdings in InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock valued at $79,000 after purchasing an additional 18,233 shares during the last quarter. Hedge funds and other institutional investors own 44.78% of the company's stock.

Insider Buying and Selling

In other InspireMD news, Director Gary S. Roubin bought 41,322 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The shares were purchased at an average cost of $2.42 per share, with a total value of $99,999.24. Following the purchase, the director directly owned 608,425 shares in the company, valued at approximately $1,472,388.50. This represents a 7.29% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Paul Stuka bought 20,661 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The shares were acquired at an average cost of $2.42 per share, for a total transaction of $49,999.62. Following the completion of the purchase, the director owned 444,195 shares in the company, valued at $1,074,951.90. This trade represents a 4.88% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 103,304 shares of company stock valued at $249,996 in the last ninety days. Company insiders own 34.06% of the company's stock.

Analysts Set New Price Targets

Separately, Piper Sandler decreased their target price on shares of InspireMD from $4.50 to $4.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $4.50.

InspireMD Trading Up 2.5%

NSPR traded up $0.06 during trading hours on Tuesday, hitting $2.46. 52,707 shares of the company's stock were exchanged, compared to its average volume of 101,203. InspireMD, Inc. has a 12-month low of $1.99 and a 12-month high of $3.80. The firm has a 50 day moving average of $2.43 and a 200 day moving average of $2.55. The firm has a market cap of $102.63 million, a P/E ratio of -3.28 and a beta of 0.68.

InspireMD Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.